Fulcrum Therapeutics (FULC) Stock Price, News & Analysis

Company Overview

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $6.56 to $7.12
• 50-Day Range: $6.35 to $8.01
• 52-Week Range: $2.32 to $10.13
• Volume: 1.01 million shs
• Average Volume: 954,870 shs
• Market Capitalization: $369.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.57
• Consensus Rating: Moderate Buy

Fulcrum Therapeutics Stock Analysis - MarketRank™

Fulcrum Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 587th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Fulcrum Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Fulcrum Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Fulcrum Therapeutics are expected to decrease in the coming year, from ($0.16) to ($1.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fulcrum Therapeutics is -5.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fulcrum Therapeutics is -5.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fulcrum Therapeutics has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.10% of the outstanding shares of Fulcrum Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Fulcrum Therapeutics has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Fulcrum Therapeutics has recently decreased by 12.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fulcrum Therapeutics does not currently pay a dividend.

Dividend Growth

Fulcrum Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.10% of the outstanding shares of Fulcrum Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Fulcrum Therapeutics has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Fulcrum Therapeutics has recently decreased by 12.77%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.48

News Sentiment

Fulcrum Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 27 news articles for Fulcrum Therapeutics this week, compared to 4 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Fulcrum Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,520.00 in company stock.

Percentage Held by Insiders

Only 7.00% of the stock of Fulcrum Therapeutics is held by insiders.

Percentage Held by Institutions

89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FULC Stock Analysis - Frequently Asked Questions

How have FULC shares performed this year?

Fulcrum Therapeutics' stock was trading at $4.70 at the beginning of the year. Since then, FULC shares have increased by 45.3% and is now trading at $6.83.

How were Fulcrum Therapeutics' earnings last quarter?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) announced its quarterly earnings data on Tuesday, July, 29th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.01.

When did Fulcrum Therapeutics IPO?

Fulcrum Therapeutics (FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO.

Who are Fulcrum Therapeutics' major shareholders?

Top institutional shareholders of Fulcrum Therapeutics include Aberdeen Group plc (0.11%), Matisse Capital (0.05%) and Vanguard Personalized Indexing Management LLC (0.02%). Insiders that own company stock include Ra Capital Management, LP, Robert J Gould and Greg Tourangeau.
View institutional ownership trends.

How do I buy shares of Fulcrum Therapeutics?

Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Fulcrum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fulcrum Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 8/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FULC
• CIK: 1680581
• Web: www.fulcrumtx.com
• Phone: (617) 651-8851
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Fulcrum Therapeutics: $7.57
• High Price Target: $12.00
• Low Price Target: $2.00
• Potential Upside/Downside: +10.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.73 million
• Net Margins: N/A
• Pretax Margin: -0.64%
• Return on Equity: -31.05%
• Return on Assets: -28.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.42
• Quick Ratio: 28.71

Sales & Book Value

• Annual Sales: $80 million
• Price / Sales: 4.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.96 per share
• Price / Book: 1.72

Miscellaneous

• Outstanding Shares: 54,090,000
• Free Float: 50,306,000
• Market Cap: $369.43 million
• Optionable: Optionable
• Beta: 2.47